Rivastigmine Tartrate
Rivastigmine Tartrate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Rivastigmine Tartrate; Generic name: RIVASTIGMINE TARTRATE; Manufacturer: Alembic Pharmaceuticals Inc..
| Brand name | Rivastigmine Tartrate |
|---|---|
| Generic name | RIVASTIGMINE TARTRATE |
| Manufacturer | Alembic Pharmaceuticals Inc. |
| Used for | 1 INDICATIONS AND USAGE Rivastigmine tartrate capsules are an acetylcholinesterase inhibitor indicated for treatment of: Mild-to-moderate dementia of the Alzheimer’s type (AD) (1.1) Mild-to-moderate dementia associated with Parkinson’s disease (PD) (1.2) 1.1 Alzheimer’s Disease Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type (AD). 1.2 Parkinson’s Disease Dementia Rivastigmine tartrate capsules are indicated for the treatment of mild-to-moderate dementia associated with Parkinson’s disease (PD). |
| Dosage | 2 DOSAGE AND ADMINISTRATION Alzheimer’s Disease (2.1): Initial Dose: Initiate treatment with 1.5 mg twice a day. Dose Titration: After a minimum of 2 weeks, if tolerated, increase dose to 3 mg twice a day and further to 4.5 mg twice a day and 6 mg twice a day if tolerated with a minimum of 2 weeks at each dose Parkinson’s Disease Dementia (PDD) (2.2): Initial Dose: Initiate treatment with 1.5 mg twice a day. Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 3 mg twice a |
| Active ingredient(s) | RIVASTIGMINE TARTRATE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0044f1d7-613c-4611-8481-13032c8cb390 |